Five Small-Cap Biotech ETF Opportunities Worth Monitoring in 2026

Exchange-traded funds have revolutionized how investors approach the biotech sector. Rather than committing capital to individual companies, small-cap biotech ETF vehicles allow investors to build exposure to multiple biotechnology firms through a single investment. This diversification strategy offers meaningful protection—if one company within the fund experiences setbacks, the overall portfolio impact remains limited. Below, we examine five small-cap biotech ETF options based on data current as of February 9, 2026, sourced from ETFdb.com.

BIB: Leveraged Daily Biotech Upside Exposure

The ProShares Ultra NASDAQ Biotechnology ETF (NASDAQ:BIB) provides investors with a unique approach to small-cap biotech positioning. Launched in April 2010 with AUM of US$89.54 million, this fund delivers twice-daily long exposure to the broad NASDAQ Biotechnology Index, making it particularly appealing for traders anticipating near-term biotech sector strength.

However, this leveraged structure carries specific risks. Financial experts caution investors with conservative risk profiles or long-term buy-and-hold strategies against this fund’s daily reset mechanism. The fund maintains 263 biotech and pharmaceutical holdings, with top positions including Gilead Sciences (NASDAQ:GILD) at 6.78 percent weight, Amgen (NASDAQ:AMGN) at 6.23 percent, and Vertex Pharmaceuticals (NASDAQ:VRTX) at 6.17 percent. The concentrated nature of its top holdings reflects broad-market biotech exposure rather than small-cap focus.

LABD: Inverse Leverage Strategy for Bear Positions

The Direxion Daily S&P Biotech Bear 3X Shares (ARCA:LABD) represents a fundamentally different approach to biotech sector engagement. With AUM of US$68.18 million, this fund is structured to deliver three times the daily inverse return of the S&P Biotechnology Select Industry Index. In practical terms, LABD gains value when the biotech sector declines and loses value when it rallies—a positioning suitable exclusively for tactical, short-term traders.

What distinguishes LABD from other small-cap biotech ETFs is its mechanism. Rather than holding individual stocks, this inverse ETF employs financial derivatives including futures contracts to achieve its objective. This structural difference carries elevated risks, particularly sensitivity to market volatility. Long-term investors should avoid this fund entirely, as the daily rebalancing mechanism destroys value over extended holding periods.

HRTS: Specialized Metabolic and Cardiac Disease Focus

Tema Heart and Health ETF (NASDAQ:HRTS) offers a narrowly focused entry into small-cap biotech exposure. Launched in November 2023 and rebranded twice—on March 25 to “Tema Heart and Health ETF” and previously as “Tema Cardiovascular and Metabolic ETF”—this fund tracks biotech firms specializing in diabetes, obesity, and cardiovascular solutions.

The fund’s 46-position portfolio tilts toward established players, with approximately 75 percent allocated to large-cap stocks and 22 percent to mid-cap positions. About three-quarters of holdings maintain US domicile. Top positions include Eli Lilly and Company (NYSE:LLY) at 10.04 percent weight, Roche Holding (OTCQX:RHHBY, SWX:ROG) at 5.42 percent, and Johnson & Johnson (NYSE:JNJ) at 4.8 percent. With AUM of US$56.55 million, this small-cap biotech ETF provides thematic exposure rather than true small-cap concentration.

GNOM: Genomics-Driven Innovation Strategy

Global X Genomics & Biotechnology ETF (NASDAQ:GNOM) tracks the Solactive Genomics Index with AUM of US$51.53 million. This fund emphasizes companies engaged in gene editing, genomic sequencing, genetic medicine, and computational genomics—the cutting edge of biotechnology innovation. The 50-stock portfolio maintains approximately 90 percent concentration in pharmaceuticals, biotechnology, and life sciences sectors.

Leading positions reflect this genomics focus: Moderna (NASDAQ:MRNA) at 6.33 percent, Arrowhead Pharmaceuticals (NASDAQ:ARWR) at 6.14 percent, and Praxis Precision Medicines (NASDAQ:PRAX) at 5.98 percent. This small-cap biotech ETF caters to investors betting on genomic technology’s transformative potential in drug development.

BBP: Equal-Weighted FDA-Approved Drug Exposure

The Virtus LifeSci Biotech Products ETF (ARCA:BBP) tracks the LifeSci Biotechnology Products Index with AUM of US$44.8 million. Launched in December 2014 by Virtus Investment Partners, this small-cap biotech ETF applies a distinctive filter: it includes only US-listed biotechnology companies with at least one FDA-approved drug therapy currently in market.

The fund’s structure emphasizes equal weighting rather than market-cap weighting, rebalanced semi-annually. This approach provides exposure across the product development spectrum, from emerging firms to established players. Top holdings include ImmunityBio (NASDAQ:IBRX) at 3.98 percent weight, Mirum Pharmaceuticals (NASDAQ:MIRM) at 2.4 percent, and Moderna at 2.16 percent. By requiring FDA-approved products, this small-cap biotech ETF removes early-stage development risk inherent in other biotech strategies.

Choosing Your Small-Cap Biotech ETF Approach

Each small-cap biotech ETF addresses distinct investor objectives. Bullish traders seeking daily leverage select BIB; tactical bearish bets require LABD; thematic investors focus on HRTS; genomics believers favor GNOM; and conservative biotech exposure demands BBP’s product-approved filter. Understanding your time horizon, risk tolerance, and investment thesis determines which small-cap biotech ETF aligns with your portfolio strategy.

This analysis represents an updated perspective on biotech ETF opportunities for 2026.